Who is sponsoring NCT03177681?

NCT03177681 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03177681?

Interventions in NCT03177681: Tongue Assessment, Stool Sample, Questionnaires, Holter Monitor, Yogurt.

What condition does NCT03177681 study?

NCT03177681 studies Malignant Neoplasms of Independent (Primary) Multiple Sites.

Is NCT03177681 still recruiting?

NCT03177681 is currently withdrawn. Last updated 27 March 2023.

Last reviewed 2023-03-27 · How we verify

NCT03177681

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms

Withdrawn NA Last updated 27 March 2023

What this trial tests

NA trial testing Tongue Assessment in Malignant Neoplasms of Independent (Primary) Multiple Sites. Withdrawn.

Timeline

1 March 2022

Primary endpoint
21 March 2023

21 March 2023

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Start date	1 March 2022
Primary completion	21 March 2023
Estimated completion	21 March 2023
Sites	1 location across United States

Drugs / interventions tested

Tongue Assessment
Stool Sample — full drug profile →
Questionnaires
Holter Monitor
Yogurt

Conditions studied

Malignant Neoplasms of Independent (Primary) Multiple Sites — all drugs for Malignant Neoplasms of Independent (Primary) Multiple Sites →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Malignant Neoplasms of Independent (Primary) Multiple Sites. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn if probiotics found in yogurt can help to decrease gastrointestinal (GI) symptoms in cancer patients. Probiotics are live bacteria and yeast that help with many of our functions and may help digestive problems. Researchers also want to learn if the bacteria in your stool change as your symptoms change while eating yogurt.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Gut Microbiota and Cancer: From Pathogenesis to Therapy.
Vivarelli S, Salemi R, Candido S, Falzone L, et al · · 2019 · cited 344× · PMID 30609850 · DOI 10.3390/cancers11010038
Postbiotics as Emerging Strategy Targeting Obesity- and Aging-Related Breast Cancer-Prospects in Prophylaxis and Therapy.
Wasiak J, Oszajca KA, Szemraj J, Witusik-Perkowska M. · · 2026 · PMID 42073437 · DOI 10.3390/life16040628

Verify or expand the search:

Other recruiting trials for Malignant Neoplasms of Independent (Primary) Multiple Sites

Currently open trials in the same condition.

NCT03435952 — Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT · Phase 1 · active not recruiting
NCT03093909 — Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases · Phase 1 · recruiting
NCT02911064 — Expectations Regarding Mobility and Self-Care · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03177681 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 27 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03177681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing